A randomised, placebo-controlled, double-blind study of adjuvant Cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma

Primary Sponsor

Collaborating Groups

TROG Cancer Research

Participating Centres

Current Accrual

Trial Chairperson

Prof Sandro Porceddu - Princess Alexandra Hospital

Trial Contact


Related Post

August 2, 2022

Celebrating and bringing radiation medicine research to the forefront at our 2022 ASM

After a hiatus from in-person events due to COVID-19

February 28, 2022

Cancer trial participant hoping to help

The RAVES trial treating prostate cancer Participating in a